Norcantharidin inhibits viability and induces cell cycle arrest and apoptosis in osteosarcoma

Osteosarcoma is the most frequent malignant bone tumor in children and adolescents. Norcantharidin (NCTD) is a purified component from blister beetles and has been identified to exert antitumor effects in a variety of cancer types. However, the antitumor effect of NCTD in osteosarcoma remains to be...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2019-01, Vol.17 (1), p.456-461
Main Authors: Zhu, Yingchun, Mi, Yunfeng, Wang, Zheyang, Jia, Xuewen, Jin, Zhanping
Format: Article
Language:English
Subjects:
Antineoplastic agents
Apoptosis
Biotechnology
Bone cancer
Care and treatment
Cell cycle
Cell growth
Fibroblasts
Genetic aspects
Membranes
Morphology
Oncology
Osteosarcoma
Proteins
Sarcoma
Software
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c510t-8c43925f47d97ffd69741ffb894c9b1da1adc23ebbf41725f6268b2a0368dd303
cites cdi_FETCH-LOGICAL-c510t-8c43925f47d97ffd69741ffb894c9b1da1adc23ebbf41725f6268b2a0368dd303
container_end_page 461
container_issue 1
container_start_page 456
container_title Oncology letters
container_volume 17
creator Zhu, Yingchun
Mi, Yunfeng
Wang, Zheyang
Jia, Xuewen
Jin, Zhanping
description Osteosarcoma is the most frequent malignant bone tumor in children and adolescents. Norcantharidin (NCTD) is a purified component from blister beetles and has been identified to exert antitumor effects in a variety of cancer types. However, the antitumor effect of NCTD in osteosarcoma remains to be elucidated. In the current study, it was first demonstrated that NCTD inhibited proliferation and induced G2/M-phase arrest and cell apoptosis in human osteosarcoma cells. Furthermore, NCTD significantly decreased the phosphorylation of Akt and the mammalian target of rapamycin in human osteosarcoma cells. These results suggest that NCTD is a promising candidate for the treatment of osteosarcoma patients in the future.
doi_str_mv 10.3892/ol.2018.9615
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6313166</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A569892923</galeid><sourcerecordid>A569892923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-8c43925f47d97ffd69741ffb894c9b1da1adc23ebbf41725f6268b2a0368dd303</originalsourceid><addsrcrecordid>eNptkstrFTEUxoMottTuXMuAIC681zxm8tgIpfiCohtdSsjk0UnJJNckU7j_vRlbr71iskg453e-cE4-AJ4juCVc4LcpbDFEfCsoGh6BU8QE3iDI8ePDnfUn4LyUG9jWQBHn9Ck4IZAOA-PsFPz4krJWsU4qe-Nj5-PkR19Ld-vV6IOv-05F08Jm0bZ02obQ6b0OtlM521J_Z9Uu7WoqvjSuS6XaVFTWaVbPwBOnQrHn9-cZ-P7h_bfLT5urrx8_X15cbfSAYN1w3ROBB9czI5hzhgrWI-dGLnotRmQUUkZjYsfR9Yg1kGLKR6wgodwYAskZeHenu1vG2RptY80qyF32s8p7mZSXx5noJ3mdbiUliCBKm8Dre4Gcfi6tLzn7sjarok1LkbhNk1DCBGroy3_Qm7Tk2NprFMUMNgb-pa5VsNJHl9q7ehWVFwMV7e8EJo3a_odq29jZ6xSt8y1-VPDqQcFkVahTSWGpPsVyDL65A3VOpWTrDsNAUK7WkSnI1TpytU7DXzwc4AH-YxTyC5fDvk8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2162709130</pqid></control><display><type>article</type><title>Norcantharidin inhibits viability and induces cell cycle arrest and apoptosis in osteosarcoma</title><source>PubMed Central</source><creator>Zhu, Yingchun ; Mi, Yunfeng ; Wang, Zheyang ; Jia, Xuewen ; Jin, Zhanping</creator><creatorcontrib>Zhu, Yingchun ; Mi, Yunfeng ; Wang, Zheyang ; Jia, Xuewen ; Jin, Zhanping</creatorcontrib><description>Osteosarcoma is the most frequent malignant bone tumor in children and adolescents. Norcantharidin (NCTD) is a purified component from blister beetles and has been identified to exert antitumor effects in a variety of cancer types. However, the antitumor effect of NCTD in osteosarcoma remains to be elucidated. In the current study, it was first demonstrated that NCTD inhibited proliferation and induced G2/M-phase arrest and cell apoptosis in human osteosarcoma cells. Furthermore, NCTD significantly decreased the phosphorylation of Akt and the mammalian target of rapamycin in human osteosarcoma cells. These results suggest that NCTD is a promising candidate for the treatment of osteosarcoma patients in the future.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2018.9615</identifier><identifier>PMID: 30655787</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Antineoplastic agents ; Apoptosis ; Biotechnology ; Bone cancer ; Care and treatment ; Cell cycle ; Cell growth ; Fibroblasts ; Genetic aspects ; Membranes ; Morphology ; Oncology ; Osteosarcoma ; Proteins ; Sarcoma ; Software ; Studies</subject><ispartof>Oncology letters, 2019-01, Vol.17 (1), p.456-461</ispartof><rights>COPYRIGHT 2019 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2019</rights><rights>Copyright © 2019, Spandidos Publications 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-8c43925f47d97ffd69741ffb894c9b1da1adc23ebbf41725f6268b2a0368dd303</citedby><cites>FETCH-LOGICAL-c510t-8c43925f47d97ffd69741ffb894c9b1da1adc23ebbf41725f6268b2a0368dd303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313166/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313166/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30655787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Yingchun</creatorcontrib><creatorcontrib>Mi, Yunfeng</creatorcontrib><creatorcontrib>Wang, Zheyang</creatorcontrib><creatorcontrib>Jia, Xuewen</creatorcontrib><creatorcontrib>Jin, Zhanping</creatorcontrib><title>Norcantharidin inhibits viability and induces cell cycle arrest and apoptosis in osteosarcoma</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Osteosarcoma is the most frequent malignant bone tumor in children and adolescents. Norcantharidin (NCTD) is a purified component from blister beetles and has been identified to exert antitumor effects in a variety of cancer types. However, the antitumor effect of NCTD in osteosarcoma remains to be elucidated. In the current study, it was first demonstrated that NCTD inhibited proliferation and induced G2/M-phase arrest and cell apoptosis in human osteosarcoma cells. Furthermore, NCTD significantly decreased the phosphorylation of Akt and the mammalian target of rapamycin in human osteosarcoma cells. These results suggest that NCTD is a promising candidate for the treatment of osteosarcoma patients in the future.</description><subject>Antineoplastic agents</subject><subject>Apoptosis</subject><subject>Biotechnology</subject><subject>Bone cancer</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Fibroblasts</subject><subject>Genetic aspects</subject><subject>Membranes</subject><subject>Morphology</subject><subject>Oncology</subject><subject>Osteosarcoma</subject><subject>Proteins</subject><subject>Sarcoma</subject><subject>Software</subject><subject>Studies</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNptkstrFTEUxoMottTuXMuAIC681zxm8tgIpfiCohtdSsjk0UnJJNckU7j_vRlbr71iskg453e-cE4-AJ4juCVc4LcpbDFEfCsoGh6BU8QE3iDI8ePDnfUn4LyUG9jWQBHn9Ck4IZAOA-PsFPz4krJWsU4qe-Nj5-PkR19Ld-vV6IOv-05F08Jm0bZ02obQ6b0OtlM521J_Z9Uu7WoqvjSuS6XaVFTWaVbPwBOnQrHn9-cZ-P7h_bfLT5urrx8_X15cbfSAYN1w3ROBB9czI5hzhgrWI-dGLnotRmQUUkZjYsfR9Yg1kGLKR6wgodwYAskZeHenu1vG2RptY80qyF32s8p7mZSXx5noJ3mdbiUliCBKm8Dre4Gcfi6tLzn7sjarok1LkbhNk1DCBGroy3_Qm7Tk2NprFMUMNgb-pa5VsNJHl9q7ehWVFwMV7e8EJo3a_odq29jZ6xSt8y1-VPDqQcFkVahTSWGpPsVyDL65A3VOpWTrDsNAUK7WkSnI1TpytU7DXzwc4AH-YxTyC5fDvk8</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Zhu, Yingchun</creator><creator>Mi, Yunfeng</creator><creator>Wang, Zheyang</creator><creator>Jia, Xuewen</creator><creator>Jin, Zhanping</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190101</creationdate><title>Norcantharidin inhibits viability and induces cell cycle arrest and apoptosis in osteosarcoma</title><author>Zhu, Yingchun ; Mi, Yunfeng ; Wang, Zheyang ; Jia, Xuewen ; Jin, Zhanping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-8c43925f47d97ffd69741ffb894c9b1da1adc23ebbf41725f6268b2a0368dd303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antineoplastic agents</topic><topic>Apoptosis</topic><topic>Biotechnology</topic><topic>Bone cancer</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Fibroblasts</topic><topic>Genetic aspects</topic><topic>Membranes</topic><topic>Morphology</topic><topic>Oncology</topic><topic>Osteosarcoma</topic><topic>Proteins</topic><topic>Sarcoma</topic><topic>Software</topic><topic>Studies</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Yingchun</creatorcontrib><creatorcontrib>Mi, Yunfeng</creatorcontrib><creatorcontrib>Wang, Zheyang</creatorcontrib><creatorcontrib>Jia, Xuewen</creatorcontrib><creatorcontrib>Jin, Zhanping</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Yingchun</au><au>Mi, Yunfeng</au><au>Wang, Zheyang</au><au>Jia, Xuewen</au><au>Jin, Zhanping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Norcantharidin inhibits viability and induces cell cycle arrest and apoptosis in osteosarcoma</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>17</volume><issue>1</issue><spage>456</spage><epage>461</epage><pages>456-461</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Osteosarcoma is the most frequent malignant bone tumor in children and adolescents. Norcantharidin (NCTD) is a purified component from blister beetles and has been identified to exert antitumor effects in a variety of cancer types. However, the antitumor effect of NCTD in osteosarcoma remains to be elucidated. In the current study, it was first demonstrated that NCTD inhibited proliferation and induced G2/M-phase arrest and cell apoptosis in human osteosarcoma cells. Furthermore, NCTD significantly decreased the phosphorylation of Akt and the mammalian target of rapamycin in human osteosarcoma cells. These results suggest that NCTD is a promising candidate for the treatment of osteosarcoma patients in the future.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>30655787</pmid><doi>10.3892/ol.2018.9615</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-1074
ispartof Oncology letters, 2019-01, Vol.17 (1), p.456-461
issn 1792-1074
1792-1082
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6313166
source PubMed Central
subjects Antineoplastic agents
Apoptosis
Biotechnology
Bone cancer
Care and treatment
Cell cycle
Cell growth
Fibroblasts
Genetic aspects
Membranes
Morphology
Oncology
Osteosarcoma
Proteins
Sarcoma
Software
Studies
title Norcantharidin inhibits viability and induces cell cycle arrest and apoptosis in osteosarcoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A21%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Norcantharidin%20inhibits%20viability%20and%20induces%20cell%20cycle%20arrest%20and%20apoptosis%20in%20osteosarcoma&rft.jtitle=Oncology%20letters&rft.au=Zhu,%20Yingchun&rft.date=2019-01-01&rft.volume=17&rft.issue=1&rft.spage=456&rft.epage=461&rft.pages=456-461&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2018.9615&rft_dat=%3Cgale_pubme%3EA569892923%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c510t-8c43925f47d97ffd69741ffb894c9b1da1adc23ebbf41725f6268b2a0368dd303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2162709130&rft_id=info:pmid/30655787&rft_galeid=A569892923&rfr_iscdi=true